ANIP 54.33 ANI Pharmaceuticals Inc $ANIP Hit a 52
Post# of 88933
Posted On: 11/18/2014 10:19:04 AM
ANIP 54.33 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high of 54.32 Closing the day 09:44 at 54.33 +1.46 +2.76% With a day low of 52.94 and a total volume of 12,313.
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 56 mins ago
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), FOLD: 6.42 (-0.28)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - 59 mins ago
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 54.35 (+1.48), CLDX: 17.48 (-0.77), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 48.09 (+0.57), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.43 (+3.01), KITE: 40.34 (+0.04), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), PBYI: 216.59 (+5.04)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 54.35 (+1.48), ICPT: 159.61 (+1.51), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 54.35 (+1.48)
ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 54.35 (+1.48), SCMP: 12.38 (+0.79)
Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 54.35 (+1.48)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), CLDX: 17.53 (-0.72), AMAG: 35.82 (+1.06)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.69 (+0.22), ANIP: 54.35 (+1.48), ACGL: 57.10 (+0.19), ACCO: 9.00 (+0.03), FLWS: 8.65 (+0.01)
ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 54.35 (+1.48)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.43 (+0.32), HBNK: 20.13 (+0.07), ASMI: 41.92 (+0.21), RRGB: 68.05 (+0.60), SAPE: 24.68 (+0.03), PLUG: 3.97 (+0.25), ANIP: 54.35 (+1.48), ODP: 6.73 (+0.04), MTEX: 22.60 (+0.09), JAXB: 11.03 (-0.02), ALQA: 5.09 (+0.13), YRCW: 23.12 (+0.48)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 6.34 (+0.22), NEO: 4.63 (+0.03), AU: 9.81 (+0.15), FNHC: 24.76 (+0.63), AMS: 2.53 (unch), NYMX: 0.53 (-0.01), AMDA: 1.33 (-0.02), CVD: 100.79 (+0.33), GBIM: 6.74 (+0.27), RCAP: 12.24 (+0.05), KBIO: 2.02 (+0.03), COOL: 0.75 (-0.01), SAPE: 24.68 (+0.03), XTLB: 2.43 (-0.15), GERN: 3.07 (+0.09), ANIP: 54.35 (+1.48), BBLU: 1.11 (-0.06), NXTD: 2.29 (+0.05), AP: 18.84 (+0.15), ALQA: 5.09 (+0.13)
ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST
ANIP: 54.35 (+1.48)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 54.35 (+1.48)
ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST
ANIP: 54.35 (+1.48)
ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI" (NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 54.35 (+1.48)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST
ACW: 4.95 (+0.03), SYY: 38.92 (+0.03), L: 42.54 (-0.05), EEP: 38.47 (+0.24), SNH: 22.18 (unch), INN: 11.54 (+0.05), ITG: 19.97 (+0.43), NSP: 32.71 (+0.11), S: 4.80 (-0.11), ALE: 50.30 (+0.21), GVA: 36.05 (+0.34), MCY: 54.36 (+0.22), ARNA: 4.53 (+0.03), CHD: 73.96 (+0.07), ARE: 82.94 (unch), USAK: 18.75 (+0.31), BWP: 16.78 (-0.12), KRG: 26.20 (+0.02), CYOU: 22.55 (unch), MNKD: 6.45 (+0.19), HNT: 51.94 (+0.85), AMH: 17.30 (+0.04), ARCB: 42.20 (-0.13), ANIP: 54.35 (+1.48), AMG: 197.47 (+2.01), HAE: 37.34 (+0.34), SOHU: 49.68 (+0.45), CNA: 39.27 (+0.16)
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 56 mins ago
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), FOLD: 6.42 (-0.28)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - 59 mins ago
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 54.35 (+1.48), CLDX: 17.48 (-0.77), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 48.09 (+0.57), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.43 (+3.01), KITE: 40.34 (+0.04), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), PBYI: 216.59 (+5.04)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 54.35 (+1.48), ICPT: 159.61 (+1.51), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 54.35 (+1.48)
ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 54.35 (+1.48), SCMP: 12.38 (+0.79)
Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 54.35 (+1.48)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), CLDX: 17.53 (-0.72), AMAG: 35.82 (+1.06)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.69 (+0.22), ANIP: 54.35 (+1.48), ACGL: 57.10 (+0.19), ACCO: 9.00 (+0.03), FLWS: 8.65 (+0.01)
ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health. ANIP: 54.35 (+1.48)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.43 (+0.32), HBNK: 20.13 (+0.07), ASMI: 41.92 (+0.21), RRGB: 68.05 (+0.60), SAPE: 24.68 (+0.03), PLUG: 3.97 (+0.25), ANIP: 54.35 (+1.48), ODP: 6.73 (+0.04), MTEX: 22.60 (+0.09), JAXB: 11.03 (-0.02), ALQA: 5.09 (+0.13), YRCW: 23.12 (+0.48)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 6.34 (+0.22), NEO: 4.63 (+0.03), AU: 9.81 (+0.15), FNHC: 24.76 (+0.63), AMS: 2.53 (unch), NYMX: 0.53 (-0.01), AMDA: 1.33 (-0.02), CVD: 100.79 (+0.33), GBIM: 6.74 (+0.27), RCAP: 12.24 (+0.05), KBIO: 2.02 (+0.03), COOL: 0.75 (-0.01), SAPE: 24.68 (+0.03), XTLB: 2.43 (-0.15), GERN: 3.07 (+0.09), ANIP: 54.35 (+1.48), BBLU: 1.11 (-0.06), NXTD: 2.29 (+0.05), AP: 18.84 (+0.15), ALQA: 5.09 (+0.13)
ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST
ANIP: 54.35 (+1.48)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 54.35 (+1.48)
ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST
ANIP: 54.35 (+1.48)
ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014. ANIP: 54.35 (+1.48)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST
ACW: 4.95 (+0.03), SYY: 38.92 (+0.03), L: 42.54 (-0.05), EEP: 38.47 (+0.24), SNH: 22.18 (unch), INN: 11.54 (+0.05), ITG: 19.97 (+0.43), NSP: 32.71 (+0.11), S: 4.80 (-0.11), ALE: 50.30 (+0.21), GVA: 36.05 (+0.34), MCY: 54.36 (+0.22), ARNA: 4.53 (+0.03), CHD: 73.96 (+0.07), ARE: 82.94 (unch), USAK: 18.75 (+0.31), BWP: 16.78 (-0.12), KRG: 26.20 (+0.02), CYOU: 22.55 (unch), MNKD: 6.45 (+0.19), HNT: 51.94 (+0.85), AMH: 17.30 (+0.04), ARCB: 42.20 (-0.13), ANIP: 54.35 (+1.48), AMG: 197.47 (+2.01), HAE: 37.34 (+0.34), SOHU: 49.68 (+0.45), CNA: 39.27 (+0.16)
(0)
(0)Scroll down for more posts ▼